Allt inom Other Corporate Information

Nanexa presented Health Economical data at international conference

Nanexa AB today presented data from a health economical study at the international health economical conference ISPOR Europe 2023 in Copenhagen, Denmark. The presentation was selected for an oral podium presentation, given by Nanexa’s Medical Director, Bengt Gustavsson, and has the title “Association between Adherence to Lenalidomide and Patient-Reported Outcomes in Patients with Multiple Myeloma: A Systematic Literature Review”.

Nanexa receives additional subscription undertaking in the ongoing rights issue

Nanexa AB (publ) (”Nanexa” or the ”Company”) announced on 21 September 2023 that the board of the Company resolved to carry out an issue of shares with preferential rights for the Company’s existing shareholders (the “Rights Issue”). Nanexa hereby announces that the Company has received an additional subscription undertaking of approximately 4.7 MSEK from one of the Company’s largest shareholders, Applied Materials Europe B.V., an affiliate of Applied Ventures, LLC, in the ongoing Rights Issue.